P53-Independent Ibrutinib Responses in an Eμ-Tcl1 Mouse Model Demonstrates Efficacy in High-Risk CLL

Blood Cancer Journal - United States
doi 10.1038/bcj.2016.41
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PTPROt-mediated Regulation of P53/Foxm1 Suppresses Leukemic Phenotype in a CLL Mouse Model

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2014English

Durable Responses After CD19-targeted CAR-T Cell Immunotherapy With Concurrent Ibrutinib for CLL After Prior Ibrutinib Failure

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL--Letter

Clinical Cancer Research
Cancer ResearchOncology
2016English

First-Line Ibrutinib Confirmed for CLL

Cancer Discovery
Oncology
2018English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

A Reductionist, in Vitro Model of Environmental Circadian Disruption Demonstrates SCN-independent and Tissue-Specific Dysregulation of Inflammatory Responses

PLoS ONE
Multidisciplinary
2019English

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

Clinical Cancer Research
Cancer ResearchOncology
2019English

Ptbp1 Regulates Alternative Splicing of Apoptotic Protein: Implications in CLL and Ibrutinib Resistance

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib for Relapsed / Refractory Cll: An Update of the Uk and Ireland Analysis of Outcomes in 315 Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy